Verastem Oncology to host Oct. 14 investor event for VS-7375 data
Verastem Oncology said it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.